Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. is registering 63,054,549 shares of Common Stock for resale by named selling securityholders under a shelf prospectus.
The prospectus states the company will not receive proceeds from these resales except for cash received upon exercise of 1,907,207 Options. The registration satisfies contractual registration rights and permits sales in varied methods and prices.
BridgeBio Oncology Therapeutics, Inc. Chief Med & Dev Officer Ben Yong reported a routine tax-related share disposition. On April 1, 2026, 1,047 shares of Common Stock were withheld by the company at $9.03 per share to cover his tax obligations upon vesting of restricted stock units. After this withholding, Yong directly holds 45,623 shares of the company’s Common Stock, indicating he retains the vast majority of his equity position and that the transaction was not an open-market sale.
BridgeBio Oncology Therapeutics, Inc. President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld at $9.03 per share to cover tax obligations from the vesting of restricted stock units.
After this tax-withholding disposition, he directly holds 45,623 shares of the company’s Common Stock. This is a routine, non–open-market event tied to equity compensation rather than an active sale in the market.
BridgeBio Oncology Therapeutics, Inc. former officer Uneek Mehra reported a small share disposition tied to taxes, not an open-market trade. On the vesting of restricted stock units, the company withheld 524 shares of Common Stock at $9.03 per share to cover tax withholding obligations. After this tax-withholding transaction, Mehra directly holds 22,806 shares of BridgeBio Oncology common stock.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of common stock for resale by selling securityholders under a post-effective amendment to its Form S-1. The registration covers (i) up to 24,343,711 PIPE Shares, (ii) up to 4,648,186 shares issued to the Sponsor and certain Helix initial shareholders, (iii) up to 32,155,445 shares issued or issuable to certain equity holders in the Business Combination, and (iv) 1,907,207 Options exercisable at $1.02–$7.88 per share.
The company will not receive proceeds from resale by the selling securityholders, except to the extent Options are exercised for cash. Sales may occur from time to time after this Registration Statement becomes effective. This amendment incorporates the company’s Form 10-K for the fiscal year ended December 31, 2025 and states no additional securities are being registered under this amendment.
BridgeBio Oncology Therapeutics, Inc. executive Marc Cobo, the Principal Accounting Officer, reported his initial ownership position on a Form 3. He directly holds 5,431 shares of Common Stock, which include 5,227 unvested restricted stock units, each representing a contingent right to receive one share upon vesting.
He also holds stock options covering 25,125 shares of Common Stock at an exercise price of $10.19 per share expiring on March 9, 2036, and options covering 129,090 shares at an exercise price of $9.59 per share expiring on August 25, 2035. These equity awards vest over time, subject to his continuous service with the company.
BridgeBio Oncology Therapeutics, Inc. executive Elmelech Idan, the COO and Principal Financial Officer, filed an initial ownership report. He holds 14,838 shares of Common Stock, which includes 14,232 unvested restricted stock units that vest in equal quarterly installments through January 1, 2030, subject to his continuous service.
Idan also directly holds several stock option awards to buy Common Stock, including 68,310 underlying shares at an exercise price of $10.19 per share expiring March 9, 2036, and 104,539 underlying shares at $9.59 per share expiring August 25, 2035. Additional options cover 7,767 shares at $7.88 per share and 129,678 shares at $4.17 per share, with expirations in 2035 and 2034. These options generally vest in 1/48th monthly installments from various start dates, contingent on continued service.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under a Prospectus Supplement No. 6 dated April 29, 2026. The supplement attaches a Form 8-K that discloses a Board and CEO succession and a consulting agreement with former director Dr. Eli Wallace.
The Form 8-K states Pedro J. Beltran, Ph.D. succeeded Dr. Wallace as President and Chief Executive Officer effective April 20, 2026, and the Company entered a consulting agreement effective April 21, 2026 for a twelve-month term that provides for continued vesting of Dr. Wallace’s outstanding equity awards and severance rights under the Company’s Executive Severance Plan.
BridgeBio Oncology Therapeutics, Inc. outlined new arrangements with former President, Chief Executive Officer and director Eli Wallace, Ph.D. The company entered into a Consulting Agreement effective retroactively from April 21, 2026, under which he will advise on research and development programs for 12 months unless ended earlier.
His compensation will be limited to continued vesting of equity awards outstanding as of the effective date, contingent on providing services through each vesting date. Vested stock options may be exercised for up to two years after his service ends or until their original expiration, whichever comes first. Under the company’s Executive Severance Plan and a Separation Agreement and Release, Wallace will also receive Tier 1 officer severance benefits tied to a termination by the company other than for cause.